Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients with Atrial Fibrillation and Recent Acute Heart Failure;Repercusiones en la posología de los anticoagulantes orales no antagonistas de la vitamina K por las variaciones de la función renal de los pacientes con fibrilación auricular e insuficiencia cardiaca aguda reciente

Revista Espanola de Cardiologia

Volumn 69, Issue 2, 2016, Pages 134-140

  Andreu Cayuelas, José M ^a   Pastor Pérez, Francisco J ^a   Puche, Carmen M ^a   Mateo Martínez, Alicia ^b   García Alberola, Arcadio ^a   Flores Blanco, Pedro J ^a   Valdés, Mariano ^a   Lip, Gregory Y H ^c   Roldán, Vanessa ^d   Manzano Fernández, Sergio ^a,e  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d HOSPITAL MORALES MESEGUER   (Spain)

^e UNIVERSITY OF MURCIA   (Spain)

Author keywords

Anticoagulants; Atrial fibrillation; Dosing; Heart failure; Renal function

Indexed keywords

APIXABAN; CREATININE; DABIGATRAN; RIVAROXABAN; ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ACUTE HEART FAILURE; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; AGED; CARDIORENAL SYNDROME; COMPLICATION; CONTRAINDICATIONS; FEMALE; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; STROKE; THROMBOEMBOLISM; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; CARDIO-RENAL SYNDROME; CREATININE; DABIGATRAN; FACTOR XA INHIBITORS; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; PYRAZOLES; PYRIDONES; RIVAROXABAN; STROKE; THROMBOEMBOLISM;

EID: 84958870112     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2015.06.022     Document Type: Article

References (37)

1. K. Damman, G. Navis, A.A. Voors, F.W. Asselbergs, T.D. Smilde, J.G. Cleland, and et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis J Card Fail. 13 2007 599 608
2. K. Damman, T. Jaarsma, A.A. Voors, G. Navis, H.L. Hillege, and D.J. Van Veldhuisen Both in-and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH) Eur J Heart Fail. 11 2009 847 854
3. V. Roldán, F. Marín, H. Fernández, S. Manzano-Fernández, P. Gallego, M. Valdés, and et al. Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding) Am J Cardiol. 111 2013 1159 1164
4. H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, W. Hacke, J. Oldgren, and et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation Europace. 15 2013 625 651
5. M. Gheorghiade, and R.O. Bonow Heart failure: early follow-up after hospitalization for heart failure Nat Rev Cardiol. 7 2010 422 424
6. M. Metra, M. Gheorghiade, R.O. Bonow, and L. Dei Cas Postdischarge assessment after a heart failure hospitalization: the next step forward Circulation. 122 2010 1782 1785
7. A.F. Hernandez, M.A. Greiner, G.C. Fonarow, B.G. Hammill, P.A. Heidenreich, C.W. Yancy, and et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure JAMA. 303 2010 1716 1722
8. R. Balasubramaniam, and P.M. Kistler Atrial fibrillation in heart failure: the chicken or the egg? Heart. 95 2009 535 539
9. T.J. Wang, M.G. Larson, D. Levy, R.S. Vasan, E.P. Leip, P.A. Wolf, and et al. Temporal relation of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study Circulation. 107 2003 2920 2925
10. E.J. Benjamin, P.A. Wolf, R.B. D'Agostino, H. Silbershatz, W.B. Kannel, and D. Levy Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation. 98 1998 946 952
11. S.M. Vaziri, M.G. Larson, E.J. Benjamin, and D. Levy Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study Circulation. 89 1994 724 730
12. D.L. Dries, D.V. Exner, B.J. Gersh, M.J. Domanski, M.A. Waclawiw, and L.W. Stevenson Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction J Am Coll Cardiol. 32 1998 695 703
13. D. Kotecha, J. Holmes, H. Krum, D.G. Altman, L. Manzano, J.G. Cleland, and et al. Efficacy of ß blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis Lancet. 384 2014 2235 2243
14. A. Banerjee, S. Taillandier, J.B. Olesen, D.A. Lane, B. Lallemand, G.Y. Lip, and et al. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project Eur J Heart Fail. 14 2012 295 301
15. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, and M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA. 285 2001 2864 2870
16. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest. 137 2010 263 272
17. G.Y. Lip, and C.J. Boos Antithrombotic treatment in atrial fibrillation Heart. 92 2006 155 161
18. K. Rewiuk, B. Wizner, M. Fedyk-Lukasik, T. Zdrojewski, G. Opolski, J.S. Dubiel, and et al. Heart failure and atrial fibrillation - does practice meet the anticoagulation guidelines? Int J Cardiol. 157 2012 274 275
19. F.R. Rosendaal, S.C. Cannegieter, F.J. Van der Meer, and E. Briët A method to determine the optimal intensity of oral anticoagulant therapy Thromb Haemost. 69 1993 236 239
20. H. Tomita, T. Kadokami, H. Momii, N. Kawamura, M. Yoshida, T. Inou, and et al. Patient factors against stable control of warfarin therapy for Japanese non-valvular atrial fibrillation patients Thromb Res. 132 2013 537 542
21. S. Apostolakis, R.M. Sullivan, B. Olshansky, and G.Y. Lip Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score Chest. 144 2013 1555 1563
22. P. Gallego, V. Roldán, F. Marin, J. Gálvez, M. Valdés, V. Vicente, and et al. SAME-TT2R2 score, time in therapeutic range and outcomes in anticoagulated patients with atrial fibrillation Am J Med. 127 2014 1083 1088
23. C.J. Boos, M. Nam, and A.J. Camm Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure Heart Fail Rev. 19 2014 391 401
24. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, and et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med. 361 2009 1139 1151
25. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, W. Hacke, and et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med. 365 2011 883 891
26. C.B. Granger, J.H. Alexander, J.J.V. McMurray, R.D. Lopes, E.M. Hylek, M. Hanna, and et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med. 365 2011 981 992
27. P.A. Reilly, T. Lehr, S. Haertter, S.J. Connolly, S. Yusuf, J.W. Eikelboom, and et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients J Am Coll Cardiol. 63 2014 321 328
28. W.G. Eisert, N. Hauel, J. Stangier, W. Wienen, A. Clemens, and J. Van Ryn Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin Arterioscler Thromb Vasc Biol. 30 2010 1885 1889
29. E. Perzborn, S. Roehrig, A. Straub, D. Kubitza, W. Mueck, and V. Laux Rivaroxaban: a new oral factor Xa inhibitor Arterioscler Thromb Biol. 30 2010 376 381
30. C. Frost, J. Wang, S. Nepal, A. Schuster, Y.C. Barrett, R. Mosqueda-Garcia, and et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects Br J Clin Pharmacol. 75 2013 476 548
31. J.W. Eikelboom, L. Wallentin, S.J. Connolly, M. Ezekowitz, J.S. Healey, J. Oldgren, and et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial Circulation. 123 2011 2363 2372
32. J.L. Halperin, G.J. Hankey, D.M. Wojdyla, J.P. Piccini, Y. Lokhnygina, M.R. Patel, and et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) Circulation. 130 2014 138 146
33. Z. Hijazi, S.H. Hohnloser, J. Oldgren, U. Andersson, S.J. Connolly, J.W. Eikelboom, and et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis Circulation. 129 2014 961 970
34. K.A. Fox, J.P. Piccini, D. Wojdyla, R.C. Becker, J.L. Halperin, C.C. Nessel, and et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment Eur Heart J. 32 2011 2387 2394
35. S.H. Hohnloser, Z. Hijazi, L. Thomas, J.H. Alexander, J. Amerena, M. Hanna, and et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial Eur Heart J. 33 2012 2821 2830
36. S. Manzano-Fernández, J.M. Andreu-Cayuelas, F. Marín, E. Orenes-Piñero, P. Gallego, M. Valdés, and et al. Comparación de las ecuaciones de filtrado glomerular estimado para determinar la posología de los nuevos anticoagulantes orales para pacientes con fibrilación auricular Rev Esp Cardiol. 68 2015 497 504
37. A.J. Camm, G.Y. Lip, R. De Caterina, I. Savelieva, D. Atar, S.H. Hohnloser, and et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation - developed with the special contribution of the European Heart Rhythm Association Europace. 14 2012 1385 1413